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Abstract
Familial Alzheimer's disease (FAD) is caused by autosomal dominant muta-
tions in the PSEN1, PSEN2 or APP genes, giving rise to considerable clini-
cal and pathological heterogeneity in FAD. Here we investigate variability in 
clinical data and the type and distribution of Aβ pathologies throughout the 
cortical layers of different FAD mutation cases. Brain tissue from 20 FAD cases 
[PSEN1 pre- codon 200 (n = 10), PSEN1 post- codon 200 (n = 6), APP (n = 4)] 
were investigated. Frontal cortex sections were stained immunohistochemi-
cally for Aβ, and Nissl to define the cortical layers. The frequency of different 
amyloid- beta plaque types was graded for each cortical layer and the severity 
of cerebral amyloid angiopathy (CAA) was determined in cortical and leptome-
ningeal blood vessels. Comparisons were made between FAD mutations and 
APOE4 status, with associations between pathology, clinical and genetic data 
investigated. In this cohort, possession of an APOE4 allele was associated with 
increased disease duration but not with age at onset, after adjusting for muta-
tion sub- group and sex. We found Aβ pathology to be heterogeneous between 
cases although Aβ load was highest in cortical layer 3 for all mutation groups 
and a higher Aβ load was associated with APOE4. The PSEN1 post- codon 
200 group had a higher Aβ load in lower cortical layers, with a small number 
of this group having increased cotton wool plaque pathology in lower layers. 
Cotton wool plaque frequency was positively associated with the severity of 
CAA in the whole cohort and in the PSEN1 post- codon 200 group. Carriers of 
the same PSEN1 mutation can have differing patterns of Aβ deposition, poten-
tially because of differences in risk factors. Our results highlight possible influ-
ences of APOE4 genotype, and PSEN1 mutation type on Aβ deposition, which 
may have effects on the clinical heterogeneity of FAD.
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1 |  INTRODUCTION
Familial Alzheimer's disease (FAD) is caused by domi-
nantly inherited mutations in APP, PSEN1 and PSEN2. 
APP generates the amyloid precursor protein (APP), 
which is cleaved to produce the amyloid- beta (Aβ) pep-
tide. PSEN1/PSEN2 are the catalytic subunits of the ƴ- 
secretase complex, which are involved in the production 
of Aβ (1, 2). As in sporadic AD, these Aβ peptides ag-
gregate into extracellular deposits as amyloid plaques, a 
classic neuropathological hallmark of AD. Although the 
causative mutations all affect proteins required for Aβ 
production, considerable heterogeneity can be seen in 
the clinical and neuropathological features, which may 
indicate individual mutation effects (3– 5).
Patients with FAD typically present with early amnes-
tic symptoms, although atypical cognitive symptoms and 
additional neurological features are also seen (3, 6, 7). 
While FAD typically causes young onset dementia, with 
age at onset usually ranging between 30 and 60  years, 
late- onset cases are increasingly found as older cohorts 
are sequenced (8, 9). In general, PSEN1 mutations cause 
younger- onset than APP mutations, while PSEN2 muta-
tions are associated with the oldest ages at onset (3, 9, 
10). PSEN1  mutation site has been found to influence 
age at onset, with mutations before codon 200 associated 
with a younger onset than those located beyond codon 
200 (3, 11). Although mutation type accounts for a large 
proportion of the variance in age at onset, substantial 
variation can still be observed even within carriers of the 
same mutation and within families (3, 6, 9). Interestingly, 
despite its role as a risk factor for sporadic AD, APOE 
genotype was not found to significantly influence age 
at onset in a meta- analysis of FAD (9). In contrast, the 
APOE4 allele has been reported to be associated with 
younger ages at onset in a single large Colombian kin-
dred harbouring the PSEN1 E280A mutation (12). Other 
factors, which are relevant in sporadic AD, may also play 
a role in clinical aspects of FAD, although they are less 
well understood. For example, females have a higher risk 
of dementia overall compared to males and in a meta- 
analysis of FAD, males showed a trend to a later age at 
onset (9).
Although symptoms tend to begin at a younger age 
when individuals’ general health is better, FAD generally 
gives rise to similar disease durations to sporadic AD (6, 
9, 13, 14). However, this too can vary within FAD, with 
PSEN2 cases reported to have longer disease durations 
than PSEN1 and APP cases (10). No difference in dura-
tion was found between APP and PSEN1 mutation car-
riers, nor between carriers of PSEN1 mutations located 
pre- and post- codon 200 (15). In a meta- analysis, shorter 
disease durations were observed in those with younger 
(<35 years) or older (>65 years) onset than in those with 
onset in mid- life (9). This same ‘inverted U- shape’ as-
sociation between age at onset and disease duration 
was found in a recent study from our centre when all 
mutations were considered together. However, it resolved 
when the different genetic groups were examined sepa-
rately as later ages at onset were associated with longer 
disease durations in PSEN1 mutation carriers, whereas 
later ages at onset were associated with shorter disease 
durations in the APP cohort. This study also found that 
survival in FAD was influenced by mutation to a much 
lesser extent than the age at onset and appeared to be 
longer in individuals with PSEN1 mutations who carried 
an APOE4 allele (14).
In FAD, the Aβ isoforms produced and the relative 
ratios of these peptide species differ between patho-
genic mutations (16, 17). A study of APP mutations has 
demonstrated that the distinct Aβ peptides produced by 
different mutations have distinct aggregation confor-
mations and so influence the type of amyloid pathology 
produced, resulting in histological diversity between 
mutations (18). Post- mortem analysis of Aβ pathology in 
FAD shows considerable heterogeneity between cases, 
with reports suggesting total Aβ may be more severe 
compared to patients with sporadic AD (19). The types 
of plaques found in the cortex are classified by their mor-
phological features (20, 21) and within PSEN1 cases the 
type and number of deposits show variability across dif-
ferent mutations (22). Additionally, between PSEN1 pre 
and post- codon 200 mutations, distinct histological phe-
notypes have been noted, with mutations post- codon 200 
tending to have more severe cerebral amyloid angiopathy 
(CAA) (11), which is the deposition of Aβ in blood vessel 
walls. Severe CAA has also been observed in cases with 
APP mutations located within the Aβ coding domain [re-
viewed in Ref. (4)]. These histological differences may be 
underlying causes of variable disease phenotypes.
As well as morphological differences between muta-
tions, there is also variability in Aβ distribution across 
the depth of the cortex. In both AD and FAD, a consis-
tent maximal density of Aβ pathology has been found in 
cortical layer 3, with varying densities in other layers (23– 
27). Additionally, Aβ plaque types have differing distri-
bution patterns over the cortical layers (28, 29). However, 
a previous study examining a group of 20 AD patients, 
including four cases with FAD mutations, reported that 
Aβ density and plaque- type distribution across the cor-
tex did not appear markedly to differ between cases, 
although the cortical layers were not specifically delin-
eated (30). Yet within FAD, certain plaque types have 
been associated with specific clinical features, such as 
the frequent observation of cotton wool plaques (CWP) 
in patients with spastic paraparesis (31, 32). These ob-
servations are particularly associated with certain muta-
tions, such as PSEN1 exon 9 deletions (33).
This study aimed to gain a deeper understanding of 
the association of genetic mutations to the morphology 
and distribution of Aβ pathology and their associations 
with disease pathogenesis in FAD. We analysed in de-
tail the morphology and distribution of Aβ pathology, 
using cortical layer- specific distributions, in a cohort of 
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20 FAD cases, using a range of measures and explored 
relationships with clinical data (age at onset and disease 
duration) and genotypes. Associations were examined 
for the cohort as a whole and also in exploratory analy-
sis in the three mutation sub- groups (PSEN1 pre- codon 
200, PSEN1 post- codon 200 and APP).
Access to FAD post- mortem tissue is limited and, 
as this was a study of cases donated to a single centre, 
our sample size was therefore small. This constrained 
our approaches when analysing the data and interpret-
ing results, particularly for analysis in the mutation 
sub- groups. In this context, while we report statistical 
significance for results in the whole cohort, our focus 
was on identifying trends and patterns. Our hypothe-
sis was that a detailed examination of Aβ pathology in 
a variety of FAD mutations would reveal differences 
in Aβ plaque- type and pattern of distribution across 
the cortical layers and in severity of CAA. We aimed 
to determine whether there are specific associations 
between the different types of Aβ pathology, and if 
these associations are observed in the FAD mutation- 
specific sub- groups.
2 |  M ATERI A LS A N D M ETHODS
2.1 | Cases
All 20 FAD cases were obtained through the brain do-
nation program of the Queen Square Brain Bank for 
Neurological Disorders (QSBB), Department of Clinical 
and Movement Neurosciences, UCL Queen Square 
Institute of Neurology and all available FAD cases 
were investigated. The protocols used for brain dona-
tion and ethical approval for this study were approved 
by a London Research Ethics Committee and tissue 
is stored for research under a license from the Human 
Tissue Authority. The standard diagnostic criteria for 
the neuropathological diagnosis of AD and the presence 
of CAA were used in all cases (34– 38).
2.2 | Histological staining and 
Immunohistochemistry
Paraffin- embedded serial sections (8 μm thick) were cut 
from the frontal cortex. For Nissl staining, deparaffin-
ised and rehydrated sections were stained with 0.1% cr-
esyl violet- acetate (83860.120, Prolabo) to determine the 
cortical layers. Serial sections were used for Aβ immu-
nohistochemistry (IHC), using a pan- Aβ antibody that 
recognises all Aβ isoforms containing residues 8– 17. 
Slides were pre- treated in formic acid followed by pres-
sure cooker in citrate buffer pH6.0. Endogenous peroxi-
dase activity was blocked with 0.3% H202 in methanol 
and non- specific binding with 10% dried milk solution. 
Sections were incubated with the primary Aβ antibody 
(1:100; M0872, DAKO) overnight at 4°C, followed by bi-
otinylated anti- mouse (1:200, 30 min; E0354, DAKO) and 
ABC complex (30  min; PK- 6100, Vector Laboratories 
Ltd). Colour was developed with di- aminobenzidine/
H2O2. Slides were scanned and digitised using a Leica 
slide scanner with a 40x objective.
2.3 | Layer delineation
Digitised Nissl sections were used to delineate the 
cortical layers, the second frontal gyrus (Brodmann 
area 9) was used for analysis. Regions of analysis 
were used in Adobe® Photoshop®  software (Adobe® 
Photoshop®  CC 2017, Adobe Systems Incorporated) 
to delineate and mark the six cortical layers. The layer 
markings were transferred onto the corresponding area 
of the serial Aβ immunohistochemically stained section 
using multiple reference points.
2.4 | Areal fraction analysis
Aβ immunohistochemically stained sections with layer 
overlay were analysed per cortical layer for percentage 
area stained (Aβ load). A 6 mm width section along the 
gyrus was analysed for all cases, although differences 
in layer depth existed between cases. For each layer 
and each case, the same volumetric area was analysed. 
Images were opened in ImageJ (39) to select individ-
ual cortical layers. For each layer, 15 randomised re-
gions of interest were generated using Python (Python 
3.6.0, Python Software Foundation) for areal fraction 
analysis. A pre- defined macro was used in ImageJ 
for threshold analysis. For each layer, the mean value 
from the 15 randomised regions of area stained was 
generated.
2.5 | Aβ plaque- type assessment
Evaluation was conducted blinded to mutation or clini-
cal information. Aβ pathology was evaluated semi- 
quantitatively based on a four- point grading scale of 
0– 3 (none, sparse, moderate and frequent). Cortical tis-
sue was assessed at 20x magnification within the same 
region as areal fraction analysis, to generate scores. We 
used the grading scale to assess Aβ plaque frequency 
for each cortical layer (1– 6) to produce a layer- specific 
score. These scores were then combined to generate an 
overall total Aβ plaque score for each case. Additionally, 
individual plaque types (diffuse, cored or CWP – iden-
tified as large circular diffuse Aβ plaques with defined 
edges) were assessed by layer (1– 6) using the same grad-
ing system and those scores combined to generate a total 
score for each plaque type. Subpial Aβ pathology was 
also assessed on the 0– 3 scale.
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2.6 | Cortical and leptomeningeal 
vessel counts
Aβ- positive cortical and leptomeningeal CAA pathology 
was determined from IHC Aβ sections. Cortical CAA was 
also assessed across the six layers using a similar 0– 3 grad-
ing scale and a combined total generated, as previously 
described (40– 42). The proportion of vessels affected by 
Aβ deposition was also analysed. Brains donated to QSBB 
are not stripped of the leptomeninges, and leptomenin-
ges were visible and present in all cases. Starting in the 
region selected for areal fraction analysis, 100 cortical ves-
sels were counted, and the proportion of affected vessels 
were calculated as a percentage. Up to 100 leptomeningeal 
vessels were counted along the meninges. Only vessels cut 
cross- sectionally showing the full circumference of the 
vessel wall were included in the analysis.
2.7 | Statistical analysis
Analyses were performed using all cases both for the 
whole cohort and by sub- groups based on mutation (in-
cluding location where relevant) or APOE4  status. The 
three mutation sub- groups were PSEN1 cases with a mu-
tation before codon 200, PSEN1 cases with a mutation 
after codon 200, and APP mutation cases. To classify 
APOE4 status, cases were separated into those without 
an ε4 allele, for example ε2/3 and ε3/3, and those with at 
least one ε4 allele, for example ε3/4 and ε4/4. For analy-
ses incorporating APOE4 status 19 cases were used, as 
DNA was not available for case 9. Statistical analyses 
were performed using STATA 15.1 (StataCorp. 2017. 
Stata Statistical Software: Release 15. College Station, 
TX: StataCorp LLC).
2.7.1 | Clinical and genetic comparisons
Linear regression models compared both age at onset and 
disease duration by: (i) mutation sub- group (adjusting 
for sex and APOE4 status); (ii) sex (adjusting for muta-
tion sub- group and APOE4 status); and (iii) APOE4 sta-
tus (adjusting for mutation sub- group and sex).
2.7.2 | Aβ pathology scores
Associations between each of the four Aβ pathology 
scores (subpial, cored plaques, diffuse plaques, CWPs) 
and the two CAA scores (cortical CAA, leptomeningeal 
CAA) and (i) age at onset, and (ii) disease duration were 
investigated in the whole cohort using linear regression, 
adjusting for APOE4 status. Each score was assessed for 
evidence of differences between mutation sub- groups 
(Kruskal– Wallis) and by APOE4  status (exact Mann– 
Whitney– Wilcoxon rank sum). All scores were then 
correlated pairwise against each other in the whole co-
hort and then in the sub- groups in order to look for any 
patterns in the correlations (Kendall's tau- b correlation 
coefficient, with statistical significance level determined 
using tables of critical values because of the small sample 
size). Finally, we compared individual layer Aβ pathology 
scores between sub- groups (Kruskal– Wallis with Dunn's 
test for pairwise comparison between sub- groups).
2.7.3 | Aβ load in the cortical tissue
Associations between mean total Aβ load (measured as a 
percentage area stained) across the six cortical layers and 
(i) age at onset and (ii) disease duration were assessed 
using a linear regression, adjusting for APOE4  status, 
in the whole cohort and in sub- groups; these analyses 
were repeated for each of the six cortical layers individ-
ually. Mean Aβ load was compared between mutation 
sub- group (Kruskal– Wallis with Dunn's test where ap-
propriate) and by APOE4 status (exact Mann– Whitney– 
Wilcoxon rank sum). Correlations between Aβ load and 
the frequency of the four different Aβ plaque pathologies 
and CAA scores were investigated in the whole cohort 
and in sub- groups in order to look for any patterns in 
the correlations (Kendall's tau- b as above). Finally, we 
assessed whether Aβ load differed between the differ-
ent layers in the whole cohort (Friedman ANOVA). The 
Aβ load of each individual layer was then compared be-
tween the mutation sub- groups, adjusted for APOE4 sta-
tus, using linear regression.
2.7.4 | Proportion of vessels affected by 
cortical CAA and leptomeningeal CAA
Linear regression models investigated whether in the 
whole cohort the proportions of vessels with CAA in the 
cortex and with CAA in the leptomeninges were associ-
ated with (i) age at onset and (ii) disease duration, adjusted 
for APOE4 status. The proportions of CAA affected ves-
sels were then compared between mutation sub- groups 
(Kruskal– Wallis and Dunn's test) and by APOE4 status 
(exact Mann– Whitney– Wilcoxon rank sum). Finally, we 
assessed whether the proportions of CAA affected vessels 
correlated with each of the four Aβ plaque pathologies 
scores and Aβ load (Kendall's tau- b as above).
3 |  RESU LTS
3.1 | Neuropathological summary
All cases reached end- stage AD with a score of A3B3C3 
according to the current diagnostic criteria, indicating 
frequent neuritic plaques, neurofibrillary pathology 
spread to the occipital cortex reaching Braak and Braak 
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stage 6 (except case 16 who scored 5) and Aβ plaque pa-
thology in the cerebellum reaching Thal stage 5.
3.2 | Clinical and genetic details
Subject details are summarised in Table 1. The 20 indi-
viduals with FAD in this study included: 16 subjects with 
PSEN1 mutations, of which 10 were located pre- codon 
200 (four intron 4, one E120K, one S132A, one M139V, 
one M146I and two E184D) and six were located post- 
codon 200 (one I202F, one L250S, two R278I, one E280G 
and one double mutation A434T & T291A), and four sub-
jects with APP mutations (one V717L and three V717I). 
There were no statistically significant differences be-
tween the APP and the two PSEN1 mutation sub- groups 
for sex or APOE4 status (Table 1).
Regression analyses for age at onset and disease du-
ration were conducted, with adjustments for mutation 
group, sex and APOE4 status, where relevant (Table 2). 
Case 9  has no APOE genotype data available so was 
not included in this analysis. The mean age at onset of 
the whole cohort, was lower in the PSEN1 pre- codon 
200  group (41.6  years) than the PSEN1 post- codon 
200 group (46.5 years) and the APP group (51.5 years). 
After adjusting for sex and APOE4 status, there was ev-
idence of an association between age at onset and mu-
tation sub- group, with mean age at onset an estimated 
8.8 years older (95% CI: 1.5, 16.1; p = 0.02) for APP com-
pared with PSEN1 pre- codon 200  mutation carriers. 
There were no other statistically significant associations 
between mutation sub- group and age at onset or disease 
duration.
In the cohort as a whole, females had a lower observed 
mean age at onset than males (42.0 years vs 49.6 years). 
After adjusting for mutation sub- group and APOE4 sta-
tus, mean age at onset was an estimated 7.3  years 
younger (95% CI: 13.1, 1.4) for females compared with 
males (p = 0.02). No evidence of an association between 
disease duration and sex was found (Table 2). No sta-
tistically significant association between APOE4 status 
and mean age at onset was found. However, there was 
strong evidence of an association between disease dura-
tion and APOE4 status, after adjusting for mutation sub- 
group and sex, with mean disease duration an estimated 
5.4 years longer (95% CI: 2.4, 8.5) for individuals with the 
APOE4 allele, compared with those without (p = 0.002) 
(Table 2).
3.3 | Aβ pathology scores
3.3.1 | Associations with clinical data
The frequency of the total Aβ pathology types (repre-
sentative images shown in Figure 1A– F) were analysed 
in relation to age at onset and disease duration. In the 
whole cohort, there were negative associations between 
leptomeningeal CAA, Aβ pathology scores (subpial pa-
thology, diffuse plaques and total cortical pathology) 
and age at onset, while cortical CAA, cored plaques 
and CWP had little association. Negative associations 
between cortical CAA, Aβ pathology scores (cored and 
diffuse plaques and total cortical pathology) and disease 
duration was also seen. However, none of the adjusted 
associations were statistically significant, with small ef-
fect sizes and large CIs (p- values ranged from p = 0.09 to 
p = 1.00, Figure 1G,H).
3.3.2 | Associations by mutation sub- groups
Microscopically, large heterogeneity in the appear-
ance of Aβ pathology was evident throughout the corti-
cal layers of the FAD cases (Figure 2). Table 3 shows the 
Aβ pathology scores for each case, giving the leptome-
ningeal CAA and subpial Aβ pathology, cortical CAA 
and plaque types in each cortical layer and the overall 
levels of Aβ plaque deposition. Observed leptomeningeal 
CAA and subpial Aβ pathology differed markedly be-
tween cases, being either absent, sparse, moderate or fre-
quent. Based on microscopic visual inspection of the Aβ 
distribution throughout the cortical layers, variations 
were also observed between carriers of the same muta-
tion. For example, one PSEN1 R278I mutation case (case 
13) contained markedly more Aβ pathology compared 
with the other PSEN1 R278I case (case 14); interestingly 
case 13 had the genotype APOE3/4 compared to case 14 
which is APOE2/3 (Figure 2). Additionally, differences 
within the pattern and distribution of plaques across the 
layers could be seen between these two cases, with case 
13 having larger and greater plaque deposition particu-
larly in layer 3, and greater cortical CAA and subpial 
deposition (Figure 2, Table 3E,A, and the subpial pathol-
ogy row). However, similarities in layer deposition could 
be seen in other carriers with the same mutation, such as 
the PSEN1 E184D carriers, with denser deposition of Aβ 
across all layers (cases 9 and 10, Figure 2). Similarly, dis-
tinct distribution patterns could be seen across different 
cases, with APP V717L case 17 and V717I cases 18 and 20 
all showing frequent subpial Aβ deposition and distinct 
plaque gradient from the upper to the lower of layer 3 
(Figure 2). In contrast, PSEN1 E120K and S132A (cases 5 
and 6) appear to have a more uniform distribution across 
layer 3 (Figure 2). Most cases showed the highest amount 
of Aβ staining within cortical layer 3, while the amount 
in the lower layers varied e.g. PSEN1 M139V (case 7) has 
very little lower layer deposition compared to the dense 
lower layer deposition seen in PSEN1 A434T & T291A 
(case 16) (Figure 2, Table 3B,D,E).
Microscopically, visual inspection of the slides re-
vealed the PSEN1 pre- codon 200 and APP groups were 
more likely to have subpial pathology (presence in 100% 
of cases) than the PSEN1 post- codon 200 group (presence 
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in 50% of cases). However, comparing each total Aβ pa-
thology score in turn formally between the three mutation 
sub- groups, there were no statistically significant differ-
ences in plaque pathology (subpial p = 0.10, cored p = 0.27, 
diffuse p = 0.46, CWP p = 0.62 and total cortical pathol-
ogy p = 0.87, global tests Kruskal– Wallis), or CAA pathol-
ogy (leptomeningeal CAA p = 0.17, cortical CAA p = 0.41). 
None of the Aβ pathologies differed by APOE4 status.
3.3.3 | Correlations between Aβ 
pathology scores
In the whole cohort, the frequency of leptomeningeal 
CAA was correlated with total cortical CAA (correlation 
coefficient τb = 0.73 p ≤ 0.001, Kendall's tau- b) (Figure 3A). 
When the sub- groups were assessed separately there was 
a consistent positive correlation (Figure 3B– D) that re-
mained in the two PSEN1 sub- groups. A trend for positive 
correlation between both total cortical and leptomenin-
geal CAA with total CWP score was seen across all groups 
except the small APP group. Specifically, in the whole co-
hort, cortical and leptomeningeal CAA scores were both 
positively correlated to total CWP scores (τb = 0.49 p < 0.01 
and τb = 0.37 p < 0.05, respectively) and in the sub- group 
analyses this correlation was particularly evident in the 
PSEN1 post- codon 200 group for cortical CAA (τb = 0.86, 
p < 0.05) and leptomeningeal CAA (τb = 0.77). In contrast, 
there was an observed trend for negative correlations 
between total cored plaque score and Aβ pathologies 
(subpial pathology, diffuse plaques, CWPs); this was par-
ticularly evident in the PSEN1 post- codon 200 group, and 
slightly evident for diffuse plaques and CWPs in the APP 
group (Figure 3A– D).
3.3.4 | Differences across cortical layers
As reported above, we did not find evidence of total 
Aβ pathology scores differing between the sub- groups. 
However, when comparing individual cortical layer 
scores (0– 3) between sub- groups we found CWPs in layer 
5 and 6 were only seen to any measurable extent in the 
PSEN1 post- codon 200  group (p  =  0.02 and p  =  0.02, 
respectively, Kruskal– Wallis). Specifically, in layer 5 
the PSEN1 post- codon 200  group had a higher CWP 
score (0.67  ±  0.82) compared to the PSEN1 pre- codon 
200  group (0  ±  0; p  =  0.01, Dunn's test) and the APP 
group (0 ± 0; p = 0.04). This pattern was also seen in layer 
6, with the PSEN1 post- codon 200 group again having a 
higher frequency of CWPs (1.0 ± 0.89) than the PSEN1 
pre- codon 200 (0.1 ± 0.32; p = 0.01, Dunn's test) and APP 
group (0.0 ± 0.0; p = 0.02, Dunn's test). There was, how-
ever, considerable layer 5 and 6 variability within the 
sub- groups. No differences for other plaque types were 
found. There were also no patterns of differences at the 
layer level in total Aβ pathology scores between APOE4 
carriers and non- carriers.
TA B L E  2  Clinical comparisons
Observed mean (years) 
(N = 20)
Model coefficient (years) 
(N = 19) 95% CI p- value
Age at onset
Mutation groupa p = 0.06
APP vs PSEN1 pre- codon 200a 51.5 vs 41.6 8.8 1.5, 16.1 p = 0.02*
APP vs PSEN1 post- codon 200a 51.5 vs 46.5 5.9 −2.0, 13.8 p = 0.13
PSEN1 pre- codon 200 vs PSEN1 post- codon 
200a 
41.8 vs 46.5 −2.9 −9.4, 3.6 p = 0.35
Females vs malesb 42.0 vs 49.6 −7.3 −13.1, −1.4 p = 0.02*
APOE4 carrier vs non- carrierc 46.3 vs 44.8 3.5 −2.5, 9.5 p = 0.23
Disease duration
Mutation groupa p = 0.73
APP vs PSEN1 pre- codon 200a 9.6 vs 9.8 0.7 −3.1, 4.4 p = 0.71
APP vs PSEN1 post- codon 200a 9.6 vs 11.5 −0.6 −4.6, 3.5 p = 0.77
PSEN1 pre- codon 200 vs PSEN1 post- codon 
200a 
9.3 vs 11.5 −1.2 −4.6, 2.1 p = 0.44
Females vs malesb 10.6 vs 9.6 −0.2 −3.2, 2.8 p = 0.89
APOE4 carrier vs non- carrierc 13.6 vs 8.0 5.4 2.4, 8.5 p = 0.002**
Note: Observed mean for whole cohort (N = 20), except for APOE where N = 19. Linear regression models compared age at onset and disease duration by mutation 
subgroup, sex and APOE4 status (N = 19). Asterisks represent statistically significant correlations.
aAdjusted for sex and APOE genotype.
bAdjusted for mutation sub- group and APOE genotype.
cAdjusted for mutation sub- group and sex.
*p < 0.05; **p < 0.01.
8 of 18 |   WILLUMSEN Et aL.
3.4 | Aβ load in the cortical tissue
3.4.1 | Associations with clinical data
Associations between mean Aβ load (measured as a 
percentage area stained) across the six cortical lay-
ers and age at onset and disease duration are shown 
in Figure 4A,B. Mean Aβ load was not statistically 
significantly associated with age at onset although a 
consistent negative association was found with mean 
Aβ load and Aβ load for individual cortical layers. 
Mean Aβ load was non- significantly positively associ-
ated with disease duration, and this trend was seen for 
most cortical layers, with evidence for an association 
found (p = 0.0003) for layer 6 Aβ load and disease du-
ration, (an estimated 0.21 additional years of duration 
for each percentage point increase in Aβ load; 95% CI: 
0.004, 0.41; p = 0.05, after adjusting for APOE4 status).
3.4.2 | By mutation sub- groups
When mean Aβ load was compared between mutation 
sub- groups, the PSEN1 post- codon 200  group had the 
highest observed mean load, followed by the APP group, 
whilst the PSEN1 pre- codon 200  group had the lowest 
(12.7% ± 6.4, 11% ± 5.5, 8.3% ± 3.8, respectively), although 
there was no statistically significant difference between 
the groups (p = 0.26 Kruskal– Wallis). Mean Aβ load was 
observed higher in APOE4 carriers than non- carriers 
(13.1% ± 5.9, 8.5% ± 4.3, respectively), although with only 
weak evidence (p = 0.08, exact Mann– Whitney– Wilcoxon 
rank sum), due perhaps to the small sample size.
3.4.3 | Correlations with Aβ 
pathology scores
Associations between Aβ load and the frequency 
of the different Aβ pathologies were investigated. 
Leptomeningeal CAA, subpial Aβ and cortical CAA 
did not significantly correlate with Aβ load. When the 
three different plaque types were examined separately, 
there was a clear trend of a negative correlation between 
cored plaque score and Aβ load, both for the whole co-
hort and for all sub- groups (Figure 4C), and this was 
statistically significant for the whole cohort (τb = −0.37, 
p < 0.01 Kendall's tau- b). This contrasted with the con-
sistently positive correlations seen between diffuse 
plaque score and Aβ load, and between CWP score and 
Aβ load; these associations were statistically significant 
for diffuse plaques in the whole cohort (p < 0.001) and in 
the PSEN1 pre- codon 200 group (p < 0.01), Figure 4C.
3.4.4 | Differences across cortical layers
Visual inspection of the cases revealed that Aβ deposi-
tion was not evenly distributed across the cortical lay-
ers (see Figure 2). In the whole cohort and within each 
F I G U R E  1  Representative images of cortical and leptomeningeal CAA (A & B), subpial pathology (C) and of Aβ plaque types (D: diffuse, 
E: Cored, F: CWP). White scale bar =50um, 200x objective. Linear regression adjusted for APOE4 status showing the association between 
total Aβ pathology scores, leptomeningeal CAA, cortical CAA and age at onset (G) and disease duration (H). Coefficient estimates and 95% 
confidence intervals for the whole cohort are represented for each total Aβ pathology score and the leptomeningeal and cortical CAA scores.
   | 9 of 18Aβ DISTRIBUTION IN FAD
mutation sub- group, observed mean Aβ load was con-
sistently numerically highest in layer 3 compared to the 
remaining layers (whole cohort 14.57%  ±  6.33; PSEN1 
pre- codon 200 12.64%  ±  6.12; PSEN1 post- codon 200 
15.99% ± 6.88; APP 17.24% ± 6.07).
We assessed whether Aβ load differed between the dif-
ferent layers. There was evidence that this was the case 
for the whole cohort (p  <  0.0001, Friedman ANOVA), 
with the highest load being observed in upper layers 2 
and 3, a pattern that was also generally seen across the 
three sub- groups (Figures 3 and 4D). The Aβ load of each 
individual layer was compared between the mutation 
sub- groups, adjusted for APOE4  status. We found evi-
dence (p = 0.007) that Aβ load in layer 5 differed between 
sub- groups, with mean Aβ load higher in the PSEN1 
post- codon 200  group compared to both the PSEN1 
F I G U R E  2  Representative images of Aβ immunohistochemically stained frontal cortex of each individual case within the mutation sub- 
groups, PSEN1 pre- codon 200 (10 cases), PSEN1 post- codon 200 (6 cases) and APP (4 cases). One Nissl stained PSEN1 Intron 4 mutation tissue 
section is shown (black box) to highlight how the layers were defined based on cellular morphology and applied to the serial Aβ section. The 
6 cortical layers are defined by white lines, with layer 1 at the pial surface and layer 6 adjacent to the white matter. Black scale bar =500µm. 
Numbers in brackets refer to case number.
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pre- codon 200  group (7.16 percentage points higher; 
95% CI: 2.9, 11.41; p = 0.003) and the APP group (6.91 
percentage points higher; 95% CI: 1.68, 12.15; p = 0.01), 
after adjusting for APOE4 status. There was weaker evi-
dence (p = 0.06) for differences in Aβ load in layer 4, with 
PSEN1 post- codon 200 cases again having higher load 
than the PSEN1 pre- codon 200 group (7.99 percentage 
points higher; 95% CI: 1.51, 14.46; p = 0.02). No signif-
icant differences were found for the other layers. These 
data suggest that mutation location may be associated 
with the distribution of pathology across some cortical 
layers but larger sub- group sizes would be needed to in-
vestigate this further.
3.5 | Proportion of cortical and 
leptomeningeal vessels affected by CAA
In our cohort, vessels positive for CAA were observed in 
the frontal cortices of the following PSEN1  mutations 
(three intron 4 mutation cases (1– 4), E120K, M146I, both 
E148D, both E280G, L250S, both R278I, double muta-
tion A434T &T291A). CAA was also present in the APP 
V717L and two APP V717I cases. Three cases (case 1: 
PSEN1 intron 4, 6: PSEN1 S132A and 19: APP V717I) 
had no CAA present in the frontal cortices.
3.5.1 | Associations with clinical data
We assessed associations between the proportions of ves-
sels with CAA in the cortex and leptomeninges and age 
at onset or disease duration. In the whole cohort, there 
was a trend for both older age at onset and longer disease 
duration to be associated with a smaller proportion of 
vessels with CAA, however these associations were not 
statistically significant (Figure S1).
3.5.2 | Differences between sub- groups
The proportion of CAA affected vessels was compared be-
tween mutation sub- groups. PSEN1 post- codon 200 cases 
had the highest observed proportion of affected vessels in 
both the cortex and leptomeninges compared to the other 
groups, with all subjects in the PSEN1 post- codon 200 mu-
tation sub- group demonstrating amyloid- beta deposition 
in at least 6% of their cortical vessels and 45% of their 
TA B L E  3  Tables showing total score of Aβ pathology type and leptomeningeal and cortical CAA per cortical layer by individual case
Note: Leptomeningeal and subpial pathology varies between cases, with presence of one not indicative of the other. (A) CAA pathology scores highlight a 
predominance of CAA in a subset of cases, with an upper layer predisposition. (B) Diffuse type plaques are seen throughout all cases to varying degrees between 
cases and within individual cases. (C&D) Cored and CWP pathology scores show that there is variation in presentation between cases, and within the same cases. 
(E) Total cortical pathology score shows that not all cases have the same level of plaque deposition. Dashed lines divide the sub- groups, PSEN1 pre- codon 200, 
PSEN1 post- codon 200 and APP.
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leptomeningeal vessels compared to a minimum of 2% 
and 0% in the PSEN1 pre- codon 200 group and 1% and 
3% in the APP group, respectively. While there was only 
very weak evidence for differences between the sub- groups 
(p = 0.10 and p = 0.08, Kruskal– Wallis), this may have been 
because of small sub- group sizes so we investigated pair-
wise comparisons. The proportion of vessels with cortical 
CAA was non- statistically higher (p  =  0.06, Dunn's test) 
in the PSEN1 post- codon 200 (40.83% ± 21.43) compared 
to the PSEN1 pre- codon 200 group (16.78% ± 17.56), and 
statistically higher (p = 0.02) compared to the APP group 
(10.75% ± 12.61). Additionally, the proportion of vessels with 
leptomeningeal CAA was higher (p = 0.07) in the PSEN1 
post- codon 200  group (71.33%  ±  18.27) compared to the 
PSEN1 pre- codon 200 group (45.43% ± 29.24), and higher 
(p = 0.01) than the APP group (30.88% ± 26.58) (Figure 5A). 
There were no differences in the proportions of cortical and 
leptomeningeal CAA by APOE4 status (p = 0.31, p = 0.47, 
exact Mann– Whitney– Wilcoxon rank sum).
3.5.3 | Correlations with Aβ pathologies
We assessed whether the proportions of cortical and 
leptomeningeal CAA affected vessels correlated with 
the total Aβ pathology scores. In contrast to the pat-
tern seen for all other Aβ pathology scores, we found a 
negative correlation between cored plaque scores and the 
F I G U R E  3  Correlation between total Aβ pathologies, leptomeningeal and cortical CAA: heat maps showing the relationship between the 
total Aβ pathology scores, leptomeningeal and cortical CAA - A) Whole cohort, B) PSEN1 pre- codon 200, C) PSEN1 post- codon 200, D) APP. 
τb values for Kendall's tau- b correlation coefficients are shown. Asterisks represent statistically significant correlations: *p < 0.05, **p < 0.01, 
***p < 0.001. Red =positive correlation. Blue = negative correlation
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proportions of both cortical and leptomeningeal CAA 
affected vessels. While these relationships did not reach 
statistical significance, the negative correlations were 
seen consistently in the whole cohort, in all sub- groups 
for cortical CAA, and in all but the small APP sub- 
group for leptomeningeal CAA (see Figure 5B,C for the 
correlation coefficients). All other total Aβ pathology 
scores were consistently positively correlated with the 
proportions of both cortical and leptomeningeal CAA 
affected vessels in the whole cohort and also in all the 
sub- groups, except again in the small APP group. As ex-
pected CAA scores and the proportions of CAA vessels 
were positively correlated and in the whole cohort this 
was statistically significant (all p < 0.001) (Figure 5B,C). 
Of particular interest were the results for CWPs, where 
in the whole cohort there was evidence for a positive cor-
relation with the proportion of cortical CAA (τb = 0.51, 
p ≤ 0.01, Kendall's tau- b) and a consistent but weaker cor-
relation with leptomeningeal CAA (τb = 0.30, p < 0.05). 
We also assessed if the mean Aβ load for the whole co-
hort was significantly associated with the proportions 
of cortical CAA or leptomeningeal CAA, with no sta-
tistically significant correlations found (τb  =  0.17 and 
τb = 0.10, respectively).
F I G U R E  4  Linear regression adjusted for APOE4 status showing the association between Aβ load and age at onset (A) and disease 
duration (B). Coefficient estimates and 95% confidence intervals for the whole cohort are represented, for the mean Aβ load and for each 
cortical layer. The coefficients are the estimated difference in the outcome (age at onset or disease duration) for a one percentage point 
increase in the explanatory variable, after adjusting for APOE4 status. *p = 0.05. (C) Correlations between Aβ load and total Aβ pathology 
scores/ leptomeningeal and cortical CAA for the whole cohort and individual mutation sub- groups. τb values for Kendall's tau- b correlation 
coefficients are shown. Asterisks represent statistically significant correlations: *p < 0.05, **p < 0.01, ***p < 0.001. Red = positive correlation. 
Blue = negative correlation. (D) Graphical display of the mean Aβ load (%) per cortical layer for the whole cohort and individual mutation sub- 
groups. Bars and error bars represent mean and SD
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4 |  DISCUSSION
In this study, we investigated associations between gen-
otype, clinical data and Aβ pathology in a cohort of 
FAD cases. We found no differences in the presence of 
Aβ pathologies and APOE status, although the overall 
amount of Aβ was found to be higher in APOE4 carriers 
than non- carriers. In all mutation carriers, the highest 
amount of Aβ was found in layer 3. Aβ load also corre-
lated with the amount of diffuse deposits found through-
out the cortical layers rather than the neuritic plaques. 
It was also of interest that two cases with the same au-
tosomal dominant mutations, R278I, displayed different 
patterns of Aβ deposition. Although one case carried an 
APOE4 allele, suggesting this may play a role in modify-
ing the deposition of Aβ. We found positive associations 
between the frequency of CWPs and both cortical and 
leptomeningeal CAA (total CAA scores and proportions 
of CAA affected vessels). Furthermore, the presence of 
CWPs was observed to be higher in lower cortical lay-
ers in some PSEN1 post- codon 200 cases, which may 
relate to observed clinical and pathological differences 
in FAD patients with mutations located post- codon 200. 
In this study we used a pan- Aβ antibody which stains 
all Aβ peptides and morphological conformations con-
taining amino acid residues 8– 17. It is clearly recognised 
within the literature that different isoforms and species 
are found in the different pathologies. However, in this 
study, we investigated the overall deposition of the Aβ 
peptides across the cortical layers rather than dissect-
ing out the isoforms present in relation to the different 
structural forms of the peptides (soluble, oligomeric or 
amyloid). This could be an interesting direction for fu-
ture work now that we have an overview of the total Aβ 
deposition.
In line with previous findings, our data show that 
mutation type is associated with age at onset in FAD. 
Specifically, PSEN1  mutations located pre- codon 
200  had a significantly earlier age at onset than APP 
mutations. In our cohort, females had an earlier age at 
onset than males, after adjusting for mutation sub- group 
and APOE4 status. A trend for younger age at onset in 
females has also been observed in a meta- analysis of 
FAD, although it did not reach statistical significance 
(9). Our findings highlight the importance of consider-
ing and investigating potential sex differences in disease 
manifestation and progression in FAD and the mech-
anisms that may be driving such differences. This is 
an area of growing interest in AD research (43), which 
could be informed by the insights gained from the study 
of FAD, where patients are typically young and lack the 
co- morbidities that can confound studies of older indi-
viduals with dementia.
Similar to findings in other FAD studies, APOE4 sta-
tus in our cohort did not affect age at onset (9, 44). 
However, we found that possession of at least one ε4 
allele was associated with longer disease duration, 
after adjusting for mutation sub- group and sex. Our 
F I G U R E  5  (A) Comparison of the proportion of cortical and leptomeningeal CAA between mutation groups. PSEN1 post- codon 200 
cases have significantly higher cortical and leptomeningeal CAA compared to the APP cases (p = 0.02 and p = 0.01, Dunn's test), with near 
significant higher proportion of cortical and leptomeningeal CAA compared to the PSEN1 post- codon 200 group (p = 0.06 and p = 0.07). Bars 
represent mean and SD. Correlations between the proportion of CAA affected vessels in the cortex (B) and leptomeninges (C) and the total Aβ 
pathology, leptomeningeal and cortical CAA scores for the whole cohort and mutation sub- groups. Kendall's tau- b τb correlation coefficients 
are shown. Red = positive correlation. Blue = negative correlation. Asterisks represent statistically significant correlations: *p < 0.05, 
**p < 0.01, ***p < 0.001
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pathological analysis did not demonstrate evidence of 
significant differences in the type, frequency or layer dis-
tribution of Aβ pathology between APOE4 carriers and 
non- carriers, raising the question of whether the differ-
ences we observed in disease duration may be mediated 
by mechanisms beyond amyloid- beta. A recent survival 
analysis from our centre (which included the individuals 
in the current study) suggested PSEN1 mutation carri-
ers with an APOE4 allele may have longer survival (14). 
However, the effect of the APOE4 genotype on disease 
duration in FAD is not well known and in sporadic AD 
its effect is uncertain. In a meta- analysis including up 
to 1,700 sporadic AD cases, it was shown to have no ef-
fect (45), however, in two prior studies of AD patients, a 
trend towards increased disease duration in APOE4 car-
riers was observed (46) and, separately, increased sur-
vival of APOE4 carriers was found (47). Our finding that 
APOE4 was associated with increased disease duration 
in this FAD cohort suggests that the impact of APOE4 
on disease progression in AD should be explored further 
in future larger studies.
In the whole cohort, total pathological Aβ plaques 
were not significantly associated with age at onset or 
disease duration. Similarly, Aβ load was not signifi-
cantly associated with age at onset, although Aβ load in 
layer 6 was positively associated with disease duration 
and this trend was consistent for the remaining layers. 
However, the associations require verifying in a larger 
cohort. Although differing Aβ distribution between in-
dividual cases was evident macroscopically, Aβ load was 
consistently higher in layer 3 for all sub- groups, as found 
in previous studies of sporadic and familial AD (25– 27, 
30,). Various hypotheses suggest an increased vulnera-
bility to AD pathomechanisms of certain neuronal pop-
ulations (48– 52). In particular, there is some evidence 
that cortical– cortical connections, predominant in layer 
3, may be particularly vulnerable (49). Interestingly, it 
has been shown in murine models that layer 3 neurons 
are more susceptible to Aβ toxicity than layer 5– 6 neu-
rons, indicating that there may be some intrinsic fac-
tor involved (53). A range of earlier studies has carried 
out investigations into amyloidogenic tau pathology in 
AD cortical tissue (indicated by senile plaques, neuritic 
plaques or NFT’s), finding this to be observed with a 
predominance for cortical layer 3 and 5 (24– 27, 54,) and 
highlighting preferential deposition and disruption in 
cortico- corticol connective regions.
Despite there being no significant differences in the 
total Aβ pathology scores between groups, a signifi-
cantly higher frequency of CWPs in layers 5 & 6 was ob-
served in the PSEN1 post- codon 200 mutation carriers. 
This finding should be interpreted with some caution 
because of the small number of subjects. However, CWP 
pathology has often been seen in kindreds and individ-
ual cases with PSEN1 mutations post- codon 200, such 
as the PSEN1 exon 9 deletion, G217R, P264L and L435F 
mutations (55– 59). This suggests certain mutations 
post- codon 200  support the development of CWPs; 
however, they can also be found in cases with PSEN1 
pre- codon 200 mutations (60). The reasons why different 
types of Aβ deposit are formed, and the role that these 
various Aβ pathologies play in AD pathogenesis, are 
not yet fully understood. One possibility is that differ-
ences in production of Aβ peptides (e.g., Aβ40, 42, 43) 
play a role in influencing plaque deposition. Different 
FAD mutations cause distinct alterations in the spec-
trum of Aβ peptides produced (16) and these peptides 
vary in their potential for aggregation, which is likely to 
influence where they deposit and how they are involved 
in any associated vascular or inflammatory processes. 
For example, two of the individuals in the post- codon 
200 group in this study carried the R278I mutation. This, 
and other post- codon 200  mutations, have been found 
to cause a particular increase in Aβ43 together with im-
pairment of PSEN1 autoproteolysis (16, 61). It has been 
speculated that altered processing of substrates other 
than APP, at an endopeptidase level, may also contribute 
to variability in the effects of PSEN1 mutations (3, 61) 
potentially representing an additional factor contribut-
ing to heterogeneity in Aβ pathology. Understanding the 
aetiology of CWPs is important because of their associa-
tion with clinical phenotypes such as spastic paraparesis 
and other motor symptoms (31, 32, 62). Motor symptoms 
and spastic paraparesis are observed more frequently in 
PSEN1 post- codon 200 cases (3, 63– 66,), supporting a 
link between the clinical phenotype and CWP pathol-
ogy. The increased frequency of CWPs in lower layers, 
especially layer 5, that we observed in our PSEN1 post- 
codon 200  mutation cohort is perhaps consistent with 
this clinicopathological association as cortical layer 5 
contains projections to the striatum, which is involved 
in motor control (67). While the evidence suggests a link, 
firm conclusions cannot be drawn as CWPs can exist 
without spastic paraparesis and CWPs can be found in 
sporadic AD, albeit infrequently (68, 69). Further in-
vestigation of the localisation of CWPs and their rela-
tionship with spastic paraparesis, particularly in PSEN1 
post- codon 200 cases, may provide more detail on how 
these observations may be linked. In future studies with 
larger cohorts, it would be of interest to also examine 
the influence of PSEN1 mutation location in more de-
tail, moving beyond a simple codon 200 cut- off to in-
vestigate the structural and functional consequences of 
mutations in different positions and how these relate to 
neuropathological features.
Analysis of the proportions of CAA revealed no sig-
nificant correlations with Aβ load; however, positive 
correlations between CAA and CWPs were found in the 
full cohort and in the PSEN1 post- codon 200 group sep-
arately using both the scoring system and vessel count 
measures. Previously, CWPs have been observed in FAD 
cases with severe CAA (70) and CWPs in FAD have been 
found to correlate with white matter hyperintensities on 
MRI, which are a potential imaging marker of CAA (42). 
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However, the precise link between these pathologies is un-
clear and interestingly CAA is predominantly composed 
of Aβ40 (71) while CWPs are composed mainly of Aβ42 
(69, 72– 74,), although Aβ40 can be present (33). Despite 
this, our findings relating to CWPs and CAA, especially in 
reference to PSEN1 post- codon 200 mutations, supports 
a pathological link, which requires verification in studies 
with larger cohorts. Given further immunohistochemical 
investigations with peptide- specific antibodies, we would 
expect to see predominance of Aβ40 in CAA and cored 
plaques, with greater abundance of Aβ42 in diffuse and 
CWP. The predisposition of Aβ40 to deposit in CAA or 
cored plaques may also account for the observed nega-
tive correlation between these two pathologies, wherein 
Aβ40 may be driven towards one of these main fates – de-
positing predominantly as either CAA or cored plaques.
In our cohort, cortical and leptomeningeal CAA were 
not correlated with age at onset or disease duration. 
There was a suggestion of differences between mutation 
sub- groups but this would require larger sample sizes to 
investigate further. Interestingly, some of our cases had 
little to no CAA, suggesting it is not an inevitable conse-
quence of Aβ pathology. Analysing a wider range of ge-
netic cases could help decipher how different mutations 
are implicated in the development of CAA, for instance, 
because of effects on PSEN1 substrates other than APP 
(75) or on Aβ profiles and their aggregation potentials 
(11, 18). Despite the heterogeneity of CAA, understand-
ing its role is important, especially as amyloid- beta mod-
ifying therapies may lead to an increase in CAA and with 
adverse vascular events in AD, with APOE status influ-
encing outcomes (76– 79).
All FAD cases in our cohort had been neuropatholog-
ically diagnosed with end- stage severe AD. This study 
focussed on the distribution of Aβ throughout the cor-
tical layers. The study did not focus on tau pathology 
as differences in tau deposition between cases would be 
difficult to observe using immunohistochemical analysis 
as the frontal cortex is full of neuropil threads. However, 
using a pan- Aβ immunohistochemical analysis binding 
the majority of Aβ species, we found that a more de-
tailed investigation of the type and layer distribution of 
amyloid- beta pathology highlighted differences between 
cases, with mutation location associated with certain 
clinical and pathological features. Broad pathologi-
cal categorisations may mask more detailed mutation- 
specific effects on pathogenic processes. Investigating 
these differences could provide better knowledge of the 
mechanisms of pathology and be an important tool for 
better understanding heterogeneity in AD. However, 
our cohort was small with only one case with certain 
mutations available. It could be misleading to gener-
alise from one mutation case to all others, and it would 
be essential to have a larger number of cases to make 
true mutation- based connections to pathological het-
erogeneity. Related to this, despite the distinct pathol-
ogy patterns we observed between mutation sub- groups, 
differences in pathology were also noted between cases 
with the same mutation indicating that other factors may 
influence pathological and clinical features in addition 
to the causative FAD mutations. We have highlighted 
some of those factors, with APOE4  genotype status 
being of importance and associated with increased dis-
ease duration. Additionally, we observed sex differences 
in age at onset with a younger age at onset in females, 
although larger studies will be needed to confirm this 
finding. Further investigation of the role of these factors 
in FAD may provide insights into how they are involved 
in the mechanisms underlying AD in general.
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